Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Prof. Ulrich Laufs
Pam R. Taub, MD, FACC, FASPC
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Christie Ballantyne, MD
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
Stephen Nicholls, FRACP, FACC, FESC, FAHA
FCS: Enhancing the Diagnosis
Daniel Gaudet, MD, PhD
The Road Ahead: What's on the Horizon for FCS and SHTG Management
Prof. Kausik Ray
Remnant Cholesterol: The Missing Link in ASCVD risk
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
SHTG: Decoding the Latest Clinical Trial Outcomes
SHTG: Defining the Unmet Clinical Need
APOC3 Inhibition: A Novel Approach to Lowering TGs
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Latest Clinical Trial Outcomes and Breakthroughs for FCS
FCS and SHTG: Are We Meeting the Need?
Ira J. Goldberg, MD
Perspectives on the results of recent clinical outcomes trials with EPA prevention
P. Gabriel Steg, MD
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Challenges in ASCVD reduction and TG-related risk
Erik Stroes
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.